Payment overview · 2025
General Payments
$503.15
22 reported records · 8 companies
Healthcare provider profile · identity verified
Jamar G Williams, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, OH · NPI 1477537371
Verified facts
What the public records show
CMS Open Payments records show Jamar G Williams, M.D. received $503.15 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 52.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $264.13 | 52.5% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $69.30 | 13.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.87 | 9.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.18 | 7.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.63 | 7.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.34 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.20 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.50 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $503.15 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $176.67 | 5 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $69.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.07 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.34 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 44 |
| Gabapentin | Gabapentin | 156 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 67 |
| Tramadol Hcl | Tramadol Hcl | 118 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 116 | 22 |
| Losartan Potassium | Losartan Potassium | 100 | 39 |
| Alprazolam | Alprazolam | 76 | 15 |
| Furosemide | Furosemide | 74 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 28 |
| Farxiga | Dapagliflozin Propanediol | 67 | 22 |
| Metformin Hcl | Metformin Hcl | 67 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 21 |
| Omeprazole | Omeprazole | 60 | 26 |
| Meloxicam | Meloxicam | 59 | 22 |
| Allopurinol | Allopurinol | 58 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Carvedilol | Carvedilol | 51 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 15 |
| Valsartan | Valsartan | 51 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 49 | 17 |
| Clonidine Hcl | Clonidine Hcl | 46 | 17 |
| Potassium Chloride | Potassium Chloride | 46 | 23 |
| Simvastatin | Simvastatin | 46 | 22 |
| Trazodone Hcl | Trazodone Hcl | 46 | 18 |
| Lisinopril | Lisinopril | 43 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 40 | 19 |
| Ozempic | Semaglutide | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 15 |
| Eliquis | Apixaban | 36 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 16 |
| Alendronate Sodium | Alendronate Sodium | 34 | 13 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 22 |
| Atenolol | Atenolol | 32 | 15 |
| Glipizide | Glipizide | 31 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Spironolactone | Spironolactone | 31 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Linzess | Linaclotide | 26 | 11 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 24 | 12 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 23 | 23 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | 13 |
| Temazepam | Temazepam | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 18 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $503.15 · 22 records | Novo Nordisk Inc | AREXVY, BodyGuardian, Dexcom G6 Transmitter, GVOKE HYPOPEN, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error